Oct 11, 2023, 21:48
Elsa Anagnostou: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print.
Elsa Anagnostou, Director of Thoracic Oncology Biorepository and Associate Professor of Oncology at Johns Hopkins Medicine, made the following post on Twitter:
“Hot off the press in Nature Medicine: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print, supporting the value of ctDNA as an early endpoint of immunotherapy response for patients with lung cancer.”
For details click here.
Source: Elsa Anagnostou/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12